Pruritus: pathogenesis, classification, diagnostics and therapeutic methods (literature review)

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Pruritus is an important problem of modern medicine, which goes far beyond dermatology.

Itching, also known as pruritus, is a complex condition marked by an unpleasant skin sensation that makes you want to scratch. This article examines the etiology, categorization, diagnosis, and treatment modalities associated with pruritus.

Histamine, cytokines, and neuropeptides are a few of the mediators involved in the pathophysiology of pruritus, along with interactions between the immune and neurological systems. Based on where it originates, pruritus can be categorized into dermatological, systemic, neuropathic, and psychogenic sources.

The focus of diagnostic techniques is on a comprehensive clinical assessment to find underlying reasons. There are many different types of treatment methods, from systemic and topical drugs to non-pharmacological techniques like behavioral therapy, phototherapy, and neuromodulation. New treatments focus on particular biochemical pathways that are responsible for itching signal transmission.

The paper presents an overview of modern views on the pathogenesis of pruritus and various methods of treatment.

全文:

受限制的访问

作者简介

Nikolay Kochergin

The First Sechenov Moscow State Medical University (Sechenov University)

Email: nkocha@yandex.ru
ORCID iD: 0000-0001-7136-4053
SPIN 代码: 1403-3031

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Syrine Smaoui

The First Sechenov Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: smaouicyrine1@gmail.com
ORCID iD: 0009-0006-1076-5674
俄罗斯联邦, Moscow

参考

  1. Carstens E, Follansbee T, Iodi CM. The challenge of basic itch research. Acta Derm Venereol. 2020;100(2):adv00023. doi: 10.2340/00015555-3343
  2. Ständer S. How to define chronic pruritus: Symptom or disease? Exp Dermatol. 2019;28(12):1461–1465. doi: 10.1111/exd.13953
  3. Ständer S, Weisshaar E, Mettang T, et al. Clinical classifcation of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291–294. doi: 10.2340/00015555-0305
  4. Villa-Arango AM, Velásquez-Lopera MM, Cardona R. [Chronic pruritus. (In Spanish)]. Rev Alerg Mex. 2019;66(1):85–98. doi: 10.29262/ram.v66i1.345
  5. Bobko SI, Tsykin AA. Cutaneous itch: The current state of the problem. Russkii medicinskii zhurnal. Dermatologiia. 2016;24(10):206–612. (In Russ.) EDN: WFEMKL
  6. Mildzikhova DR, Nevozinskaya ZA, Sakaniya LR, Korsunskaya IM. Skin itching--actual interdisciplinary problem. Klinicheskaia dermatologiia i venerologiia = Russian journal of Clinical dermatology and venereology. 2020;19(1):101–104. EDN: HCVBVT doi: 10.17116/klinderma202019011101
  7. Welz-Kubiak K, Reszke R, Szepietowski JC. Pruritus as a sign of systemic disease. Clin Dermatol. 2019;37(6):644–656. doi: 10.1016/j.clindermatol.2019.07.031
  8. Song J, Xian D, Yang L, et al. Pruritus: Progress toward pathogenesis and treatment. Biomed Res Int. 2018;2018:9625936. doi: 10.1155/2018/9625936
  9. Welz-Kubiak K, Reszke R, Szepietowski JC. Pruritus as a sign of systemic disease. Clin Dermatol. 2019;37(6):644–656. doi: 10.1016/j.clindermatol.2019.07.031
  10. Communie A, Brenaut E, et al. Metameric pruritus as the sole manifestation of an intramedullary tumor in a toddler. Pediatric Dermatology. 2023;41(1):160–161.
  11. Bonamigo RR, editor. Dermatology in public health environments. A comprehensive textbook. Second Edition. Springer Nature Switzerland AG; 2023. 2201 p. doi: 10.1007/978-3-031-13505-7
  12. Stander S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: Women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168(6):1273–1280. doi: 10.1111/bjd.12267
  13. Chung BY, Um JY, Kim JC, et al. Pathophysiology and treatment of pruritus in elderly. Int J Mol Sci. 2020;22(1):174. doi: 10.3390/ijms22010174
  14. Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: A population based cross-sectional study. Acta Derm Venereol. 2011;91(6):674–679. doi: 10.2340/00015555-1159
  15. Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506. doi: 10.2340/00015555-3164
  16. Weisshaar E, Dalgard F. Epidemiology of itch: Adding to the burden of skin morbidity. Acta Derm Venereol. 2009;89(4):339–350. doi: 10.2340/00015555-0662
  17. Yang Y, Sun Y, Zhu C, et al. Allantoin induces pruritus by activating MrgprD in chronic kidney disease. J Cell Physiol. 2023;238(4):813–828. doi: 10.1002/jcp.30977
  18. Forouhari A, Moghtaderi M, Raeisi S, et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients: A cross-over randomized clinical trial. Hemodialysis Int. 2022;26(3):408–414. doi: 10.1111/hdi.13007
  19. Nietsche TR, Dotta G, Barcaui CB, Ferraz ML. Cholestatic pruritus: A knowledge update. Ann Bras Dermatol. 2022;97(3):332–337. doi: 10.1016/j.abd.2021.06.007
  20. Düll MM, Kremer AE. Treatment of pruritus secondary to liver disease. Curr Gastroenterol Rep. 2019;21(9):48. doi: 10.1007/s11894-019-0713-6
  21. Yosipovitch G, Greaves M, Schmelz M. Itch. Lancet. 2003;361(9358):690–694. doi: 10.1016/S0140-6736(03)12570-6
  22. Navarro-Triviño FJ. [Pruritus in dermatology. Part I: General concepts and pruritogens. (In English, Spanish)]. Actas Dermosifiliogr. 2023;114(6):512–522. doi: 10.1016/j.ad.2023.03.003
  23. Kouwenhoven TA, van Muijen ME, van de Kerkhof PC, et al. Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic reviewin pediatric patients. Pediatr Dermatol. 2024;41(1):34–40. doi: 10.1111/pde.15468
  24. Song J, Xian D, Yang L, et al. Pruritus: Progress toward pathogenesis and treatment. Biomed Res Int. 2018;2018:9625936. doi: 10.1155/2018/9625936
  25. Адаскевич В.П. Кожный зуд. Дерматологический и междисциплинарный феномен. Москва: БИНОМ. Лаборатория знаний, 2014. 272 с. Adaskiewicz VP. Cutaneous itching. Dermatological and interdisciplinary phenomenon. Moscow: BINOM. Laboratoriya znanii; 2014. 272 с. (In Russ.)
  26. Nakashima C, Ishida Y, Kitoh A, et al. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405–1411. doi: 10.1111/exd.14014
  27. Papageorgiou C, Lazaridou E, Lallas K, et al. A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management. Photodermatol Photoimmunol Photomed. 2023;39(5):506–511. doi: 10.1111/phpp.12892
  28. Sanjel B, Kim BH, Song MH, et al. Glucosylsphingosine evokes pruritus via activation of 5-HT2Areceptor and TRPV4in sensory neurons. Br J Pharmacol. 2022;179(10):2193–2207. doi: 10.1111/bph.15733
  29. LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Neurosci. 2014;15(1):19–31. doi: 10.1038/nrn3641
  30. Fowler E, Yosipovitch G. Chronic itch management: Therapies beyond those targeting the immune system. Ann Allergy Asthma Immunol. 2019;123(2):158–165. doi: 10.1016/j.anai.2019.01.016
  31. Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci. 2010;33(12):550–558. doi: 10.1016/j.tins.2010.09.002
  32. Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain. 2008;4:29. doi: 10.1186/1744-8069-4-29
  33. Pogatzki-Zahn EM, Pereira MP, Cremer A, et al. Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus. J Invest Dermatol. 2020;140(1):203–211.e4. doi: 10.1016/j.jid.2019.05.029
  34. Huang JF, Thurmond R. The new biology of histamine receptors. Curr Allergy Asthma Rep. 2008;8(1):21–27. doi: 10.1007/s11882-008-0005-y
  35. Snyder LM, Kuzirian MS, Ross SE. An unexpected role for TRPV4 in serotonin-mediated itch. J Investig Dermatol. 2016;136(1):7–9. doi: 10.1016/j.jid.2015.11.010
  36. Ständer S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Br J Dermatol. 2019;181(5):932–938. doi: 10.1111/bjd.18025
  37. James WD, Elston DM, Treat JR, et al. Andrews’ diseases of the skin. Clinical dermatology. 13th edition. Elsevier, 2020. 933 p.
  38. Tarikci N, Kocatürk E, Güngör Ş, et al. Pruritus in systemic diseases: A review of etiological factors and new treatment modalities. Scientifc World J. 2015;2015:803752. doi: 10.1155/2015/803752
  39. Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol. 2019;10:1383. doi: 10.3389/fimmu.2019.01383
  40. Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with interleukin 2 administration. JAMA. 1987;258(12):1624–1629.
  41. Ko MJ, Peng YS, Chen HY, et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol. 2014;71(6):1151–1159.e1. doi: 10.1016/j.jaad.2014.08.004
  42. Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29–36. doi: 10.1111/all.13239
  43. Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: A literature review. Acta Derm Venereol. 2012;92(5):555–560. doi: 10.2340/00015555-1353
  44. Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176–6180. doi: 10.1523/JNEUROSCI.23-15-06176.2003
  45. Carstens E, Akyama T, editors. Itch: Mechanisms and treatment. Book. 1st ed. Boca Raton, FL: CRC Press, 2014. 494 р. doi: 10.1201/b16573
  46. Xie Z, Hongzhen H. TRP channels as drug targets to relieve itch. Pharmaceuticals (Basel). 2018;11(4):100. doi: 10.3390/ph11040100
  47. Indo Y. Nerve growth factor, pain, itch and infammation: Lessons from congenital insensitivity to pain with anhidrosis. Expert Rev Neurother. 2010;10(11):1707–1724. doi: 10.1586/ern.10.154
  48. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by cannabinoid receptor agonist in human skin. Infamm Res. 2003;52(6):238–245. doi: 10.1007/s00011-003-1162-z
  49. Papadopoulou N, Kalogeromitros D, Staurianeas NG, et al. Corticotropinreleasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol. 2005;125(5):952–955. doi: 10.1111/j.0022-202X.2005.23913.x
  50. Cowan A, Yosipovitch G, editors. Pharmacology of itch. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag, 2015. doi: 10.1007/978-3-662-44605-8
  51. Katsambas AD, Lotti TM, Dessinioti C, d‘Erme AM, editors. European handbook of dermatological treatments. Fourth Edition, Springer Nature Switzerland AG; 2023. 1830 р. doi: 10.1007/978-3-031-15130-9
  52. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: A new measure of pruritus. Br J Dermatol. 2010;162(3):587–593. doi: 10.1111/j.1365-2133.2009.09586.x
  53. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch severity scale: A self-report instrument for the measurement of pruritus severity. Br J Dermatol. 2007;156(4):667–673. doi: 10.1111/j.1365-2133.2006.07736.x
  54. Reich A, Mędrek K, Szepietowski JC. Four-item itch questionnaire: Validation of questionnaire. Przegl Dermatol. 2012;99:600–604.
  55. Reich A, Bożek A, Janiszewska K, Szepietowski JC. 12-item pruritus severity scale: Development and validation of new itch severity questionnaire. Biomed Res Int. 2017;2017:3896423. doi: 10.1155/2017/3896423
  56. Baka P, Birklein F. [Neuropathic pruritus-Evidence-based treatment recommendations. (In German)]. Nervenarzt. 2023;94(2):136–141. doi: 10.1007/s00115-022-01369-0
  57. Suzuki H, Yamauchi K, Uchida S. Approach using the bath preparation containing rice extract for severe pruritus in a patient receiving hemodialysis: A case report. Clin Case Rep. 2024;12(3):e8638. doi: 10.1002/ccr3.8638
  58. Spickett G, editor. Oxford handbook of clinical immunology and allergy. Fourth edition. 4th Edition. Oxford University Press, 2020. 677 p.
  59. Papoiu AD, Yosipovitch G. Topical capsaicin. The fre of a “hot” medicine is reignited. Expert Opin Pharmacother. 2010;11(8):1359–1371. doi: 10.1517/14656566.2010.481670
  60. Patel T, Ishiuji Y, Yosipovitch G. Menthol: A refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57(5):873–878. doi: 10.1016/j.jaad.2007.04.008
  61. Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol. 2012;66(2):327–328. doi: 10.1016/j.jaad.2011.05.024
  62. Harrison IP, Spada F. Breaking the Itch-scratch cycle: Topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines (Basel). 2019;6(3):76. doi: 10.3390/medicines6030076
  63. Guttman-Yassky E, Hanifn JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28(1):3–10. doi: 10.1111/exd.13808
  64. Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a nonsteroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98(5):484–489. doi: 10.2340/00015555-2893
  65. Honda T, Kabashima K. Prostanoids and leukotrienes in the pathophysiology of atopic dermatitis and psoriasis. Int Immunol. 2019;31(9):589–595. doi: 10.1093/intimm/dxy087
  66. O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi: 10.1146/annurev-med-051113-024537
  67. Zhong Y, Xu H, Zhong Y, et al. Identifcation and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of tropomyosin receptor kinase A. BMC Complement Altern Med. 2019;19(1):295. doi: 10.1186/s12906-019-2709-z
  68. Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: Results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–548. doi: 10.2340/00015555-2047
  69. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin infammation in mice and humans. J Investig Dermatol. 2017;137(10):2110–2119. doi: 10.1016/j.jid.2017.05.004
  70. Korsunskaya IM, Dvoryankova YeV, Melnichenko OO, Panyukova SV. Skin itching: What should we think about. Effective pharmacotherapy. 2015;(45):14–18. EDN: TBAJFW
  71. Vyalov SS. Cutaneous pruritus: differential diagnosis, principles of rational pharmacotherapy. Russkii meditsinskii zhurnal. 2015;23(19):1142–1145. (In Russ.) EDN: VHFSZN
  72. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368(17):1625–1634. doi: 10.1056/NEJMcp1208814
  73. Misbah SA, Spickett GP, Dalm VA, seventh edition. Chapel and haeney’s essentials of clinical immunology. Wiley-Blackwell, John Wiley & Sons Ltd; 2022. 374 p.
  74. Reszke R, Szepietowski JC. Can we use psychoactive drugs to treat pruritus? Exp Dermatol. 2019;28(12):1422–1431. doi: 10.1111/exd.13959
  75. Steinhoff M, Cevikbas F, Ikoma A, Berger TG. Pruritus: Management algorithms and experimental therapies. Semin Cutan Med Surg. 2011;30(2):127–137. doi: 10.1016/j.sder.2011.05.001
  76. Edwards AM, Stevens MT, Church MK. The effects of topical sodium cromoglicate on itch and fare in human skin induced by intradermal histamine: A randomised double-blind vehicle controlled intra-subject design trial. BMC Res Notes. 2011;4:47. doi: 10.1186/1756-0500-4-47
  77. Shneider BL, Spino C, Kamath BM, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome. Hepatol Commun. 2018;2(10):1184–1198. doi: 10.1002/hep4.1244
  78. Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3(3):365–381. doi: 10.1002/hep4.1305
  79. Al-Dury S, Wahlström A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8(1):6658. doi: 10.1038/s41598-018-25214-0
  80. Hegade VS, Pechlivanis A, McDonald JA. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver Int. 2019;39(5):967–975. doi: 10.1111/liv.14069
  81. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment withs systemic μ-opioid receptor antagonists: A review. J Am Acad Dermatol. 2010;63(4):142–148. doi: 10.1016/j.jaad.2009.08.052
  82. Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41(4):371–382. doi: 10.1111/jcpt.12404
  83. Yang Y, Guo L, Chen Z, et al. Benefits and harms of NK1R antagonists in pruritus: A systematic review and meta-analysis. Dermatol Ther. 2021;34(1):e14698. doi: 10.1111/dth.14698
  84. Alam M, Buddenkotte J, Ahmad F, Steinhoff M. Neurokinin 1 receptor antagonists for pruritus. Drugs. 2021;81(6):621–634. doi: 10.1007/s40265-021-01478-1
  85. Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182. doi: 10.1016/j.jaci.2019.08.013
  86. Zhou T, Zhang Y, Ma Y, et al. Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial. Cancer. 2022;128(22):3969–3976. doi: 10.1002/cncr.34474
  87. Heitman A, Xiao C, Cho Y, et al. Tradipitant improves worst itch and disease severity in patients with chronic pruritus related to atopic dermatitis. J Am Acad Dermatol. 2018;79:AB300.
  88. Reszke R, Krajewski P, Szepietowski JC. Emerging therapeutic options for chronic pruritus. Am J Clin Dermatol. 2020;21(5):601–618. doi: 10.1007/s40257-020-00534-y
  89. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: 10.1016/j.jaad.2016.12.005
  90. Leal RP, Hoyos CL, Echevarría AG, et al. Aquagenic pruritus successfully treated with upadacitinib. Australas J Dermatol. 2024;65(4):390–392. doi: 10.1111/ajd.14228
  91. Wang W, Zhou L, Sun L. Ondansetronfor neuraxial morphine-induced pruritus: A meta-analysis ofrandomized controlled trials. J Clin Pharm Ther. 2017;42(4):383–393. doi: 10.1111/jcpt.12539
  92. Mollie SH, Friedlander BA. Aquagenic pruritus in an adolescent effectively managed with β-alanine supplementation. Pediatric Dermatology. 2021;38(1):320–321. doi: 10.1111/pde.14440
  93. Legat FJ. The antipruritic effect of phototherapy. Front Med (Lausanne). 2018;5:333. doi: 10.3389/fmed.2018.00333
  94. Yosipovitch G, Greaves MW, Fleischer AB, Jr., ed. Itch. Basic mechanisms and therapy. Francis McGlone, New York, Basel; 2004. 388 p.
  95. Witte JP, Kravchenko D, Marinova M, et al. Matrix stimulation in chronic pruritus: A randomized controlled study. J Dermatol. 2020;47(10):1166–1174. doi: 10.1111/1346-8138.15492
  96. Eliseev DN, Temnikov VE, Ivanov AO, Eliseev GD, Bezkishkij JN. Aerocryotherapy as non-pharmacological means of correction of the functional status of patients with atopic dermatitis. Bull Pirogov National Med Surg Center. 2014;9(2):87–91. EDN: WZCGPJ
  97. Olisova OYu, Kayumova LN, Smirnov KV, Shuppo OA, Arsentyev NS. General cryotherapy with the use of cryocapsule icequeen in patients with various dermatoses. Russ J Skin Venereal Dis = Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2017;20(1):15–20. EDN: YGTAIR doi: 10.18821/1560-9588-2017-20-1-15-20
  98. Bewley A, Lepping P, Taylor RE, ed. Psychodermatology in clinical practice. Springer Nature Switzerland AG; 2021. P. 312–318. doi: 10.1007/978-3-030-54307-5
  99. Buteau A, Reichenberg J. Psychogenic pruritus and its management. Dermatol Clin. 2018;36(3):309–314. doi: 10.1016/j.det.2018.02.015
  100. Akhtyamov SN, Butov YS, Vasenova VY, et al. Dermatovenerology: A guide for doctors. Moscow: GEOTAR-Media; 2017. 640 р. (In Russ.)
  101. Pritulo OA. Dermatology and venereology: Textbook. Moscow: INFRA-M; 2022. 204 р. (In Russ.)

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2024


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.